RA Capital Management 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 85 US equity positions worth $6.0bn in its Q1 2025 13F filing. The largest position was ASND at 26.6% of the reported book, followed by PCVX and RYTM. Against the Q4 2024 filing, it opened 5 new positions, added to 13 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 26.6% | $1.6bn | 10,281,496 | 2% | added |
| 2 | PCVX VAXCYTE INC | Healthcare | 7.6% | $460.3m | 12,189,149 | 40% | added |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 5.4% | $322.3m | 6,084,412 | 0% | held |
| 4 | JANX JANUX THERAPEUTICS INC | Healthcare | 5.0% | $302.1m | 11,189,693 | 8% | added |
| 5 | NEWAMSTERDAM PHARMA CO NV | 3.4% | $207.5m | 10,138,938 | 15% | added | |
| 6 | ARCELLX INC | 3.3% | $199.2m | 3,036,527 | 9% | added | |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | 3.3% | $196.0m | 8,909,091 | 0% | held | |
| 8 | AVIDITY BIOSCIENCES INC | 3.1% | $186.0m | 6,300,408 | 0% | held | |
| 9 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.4% | $147.1m | 18,202,009 | 0% | held |
| 10 | 89BIO INC | 2.4% | $144.6m | 19,889,683 | 40% | added | |
| 11 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 2.3% | $136.6m | 10,860,977 | 0% | held |
| 12 | SION SIONNA THERAPEUTICS INC | 1.8% | $109.3m | 10,445,322 | – | new | |
| 13 | LENZ LENZ THERAPEUTICS INC | Healthcare | 1.8% | $107.4m | 4,178,823 | 0% | held |
| 14 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.7% | $101.6m | 9,714,392 | 52% | added |
| 15 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.6% | $98.9m | 10,637,290 | 0% | held |
| 16 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.6% | $97.6m | 6,147,280 | 27% | added |
| 17 | GERN GERON CORP | Healthcare | 1.6% | $96.0m | 60,379,366 | 101% | added |
| 18 | RXST RXSIGHT INC | Healthcare | 1.6% | $94.5m | 3,743,018 | 0% | held |
| 19 | BCAX BICARA THERAPEUTICS INC | 1.5% | $90.6m | 6,955,993 | 0% | held | |
| 20 | IRON DISC MEDICINE INC | Healthcare | 1.3% | $78.3m | 1,577,106 | – | new |
| 21 | GHRS GH RESEARCH PLC | 1.3% | $76.6m | 6,944,648 | 4% | added | |
| 22 | CLYM CLIMB BIO INC | 1.2% | $70.6m | 31,419,267 | 0% | held | |
| 23 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.0% | $58.6m | 1,569,491 | 0% | held |
| 24 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.9% | $52.0m | 2,866,733 | 54% | added |
| 25 | ZLAB ZAI LAB LTD-ADR | Healthcare | 0.8% | $46.8m | 1,295,040 | 0% | held |
| 26 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 0.8% | $45.6m | 5,755,577 | 0% | held | |
| 27 | SEPN SEPTERNA INC | 0.7% | $40.5m | 6,995,858 | 0% | held | |
| 28 | TOURMALINE BIO INC | 0.6% | $38.6m | 2,538,925 | 0% | held | |
| 29 | SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 0.6% | $36.5m | 1,136,453 | 6351% | added |
| 30 | URGN UROGEN PHARMA LTD | Healthcare | 0.6% | $35.5m | 3,206,271 | – | new |
| 31 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.5% | $29.6m | 9,853,302 | 0% | held | |
| 32 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.5% | $29.5m | 10,229,099 | 0% | held |
| 33 | VOR VOR BIOPHARMA INC | 0.5% | $28.4m | 39,646,039 | 0% | held | |
| 34 | ASTRIA THERAPEUTICS INC | 0.5% | $27.3m | 5,105,213 | 0% | held | |
| 35 | KURA KURA ONCOLOGY INC | Healthcare | 0.4% | $26.4m | 4,004,610 | -10% | reduced |
| 36 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.4% | $26.3m | 1,517,418 | 0% | held |
| 37 | CDTX CIDARA THERAPEUTICS INC | 0.4% | $23.5m | 1,092,796 | 0% | held | |
| 38 | AEROVATE THERAPEUTICS INC | 0.4% | $23.1m | 9,192,092 | 0% | held | |
| 39 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.4% | $22.1m | 1,347,252 | 0% | held |
| 40 | ITEOS THERAPEUTICS INC | 0.4% | $21.8m | 3,649,057 | 74% | added | |
| 41 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.3% | $20.6m | 1,150,000 | 0% | held |
| 42 | NKTX NKARTA INC | Healthcare | 0.3% | $19.9m | 10,805,129 | 0% | held |
| 43 | GKOS GLAUKOS CORP | Healthcare | 0.3% | $18.7m | 190,256 | – | new |
| 44 | MNPR MONOPAR THERAPEUTICS INC | 0.3% | $18.6m | 511,207 | 0% | held | |
| 45 | METSERA INC | 0.3% | $18.4m | 675,525 | – | new | |
| 46 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 0.3% | $17.2m | 3,181,818 | 0% | held |
| 47 | TXG 10X GENOMICS INC-CLASS A | Healthcare | 0.3% | $17.0m | 1,944,247 | -41% | reduced |
| 48 | ACRV ACRIVON THERAPEUTICS INC | 0.3% | $16.9m | 8,340,508 | 0% | held | |
| 49 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.3% | $16.7m | 848,986 | 0% | held |
| 50 | ABOS ACUMEN PHARMACEUTICALS INC | 0.3% | $16.4m | 14,932,063 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.